Table 2.

A proposed classification system for the treatment of hepatitis C virus in the direct-acting antiviral era.

Class I: treatment naïve, IT, G2/3, G1 low viral load, and/or CC allele (20–25% of US patients)

Class II: treatment naïve, IT, G1 high viral load, or CT/TT allele (40–50% of US patients)

Class III: G1/4 and G2/3 relapsers and nonresponders to current standard of care who become RNA undetectable by week 12 of treatment (20% of US patients)

Class IV: Class IIIs who do not become undetectable by week 12, interferon-intolerant patients and all treatment failures from treated Classes I–III (30% US patients assuming 5% from Classes I and III, and 10% from Class II)

CC, IL28B allele genotype C/C; CT, IL28B allele genotype C/T; IT, interferon tolerant; TT, IL28B allele genotype T/T.